Zogenix CEO and leadership

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

Gail Farfel joined Marinus as the company's Chief Clinical Development and Regulatory Officer in January 2010. Previously, Dr. Farfel worked at Novartis Pharmaceuticals Corp. (US subsidiary of Novartis AG) as Vice President, Therapeutic Area Head for Neuroscience Clinical Development and Medical Affairs. At Novartis Dr. Farfel oversaw a portfolio of products including Gilenya (fingolimod), Exelon and the Exelon Patch, and the antidepressant agomelatine. Prior to Novartis, Dr. Farfel held a variety of leadership positions in Clinical Development and Global Medical Affairs at Pfizer, Inc. where she directed programs through all stages of clinical development and regulatory submissions including development of the first product approved globally to treat Posttraumatic Stress Disorder. Dr. Farfel holds an Ph.D. in Neuropsychopharmacology from The University of Chicago, where she trained as a behavioral scientist and neurotoxicologist, and received the Ginsburg Prize for Dissertation Excellence. She has a Bachelor's degree in Biochemistry from The University of Virginia, and is the author of over 50 scientific articles in the areas of neuropsychopharmacology and drug treatment. She serves as an advisor to Ariotech and on the board of PrintedArt.

Michael Smith is a Global Corporate Executive and Board Advisor in the Manufacturing and Specialty Chemical sectors, recognized for leveraging his extensive experience leading complex global businesses, partnering with C-Suite and Boards on strategic business development initiatives in executive, committee and board roles. He has led $150M to $900M revenue businesses, managing P&L and overseeing all sales, marketing, finance, operations, technology, supply chain, business development, and human resources functions. Michael’s broad experience in manufacturing and specialty chemicals has most recently focused on expanding business via new market entry and M&A. Consistently delivering record earnings performance, driving innovative customer-focused solutions and operational efficiencies he has designed and implemented strategies for manufacturing operations during periods of growth and downturn, as well as through M&A integration and organization restructuring.

Global leadership experience in driving profitable growth and financial returns, launching complex business models, building high performing commercial teams, commercializing complex technologies and specialty therapies.

Bradley 'Brad Gale' Galer is an Exec VP/Chief Medical Officer at Zogenix Inc.; President:Pain Group at fqubed, Inc.; and VP:Enhanced Recovery at Encore Acquisition Co. He has worked as Pres:Pain Group at Nuvo Pharmaceuticals Inc, Group VP:Scientific Affairs at ENDO INTERNATIONAL, and Board Member at Nuvo Pharmaceuticals Inc. Bradley works or has worked at CONOCOPHILLIPS and works or has worked as VP/General Manager at fqubed, Inc.. He attended MARIETTA COLLEGE.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.

Stephen J. Farr, Ph.D. is one of our co-founders and has served as our President and as a member of our board of directors since August 2006. From 1995 to August 2006, Dr. Farr held positions of increasing responsibility within pharmaceutical sciences and research and development at Aradigm Corporation, and he served most recently as Senior Vice President and Chief Scientific Officer. In 2003, he played a key role in identifying and acquiring the DosePro technology and became technical director and executive sponsor for the development of sumatriptan DosePro at Aradigm Corporation. From 1986 to 1994, Dr. Farr was a tenured professor at the Welsh School of Pharmacy, Cardiff University, United Kingdom, concentrating in the areas of physical pharmacy and biopharmaceutics. He is a fellow of the American Association of Pharmaceutical Scientists and visiting Associate Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. Dr. Farr is a registered pharmacist in the United Kingdom and obtained his Ph.D. degree in Pharmaceutics from the University of Wales.